Matthias Helms

Title: Matthias Helms: A Pioneer in the Preparation of Enantiomeric Trisubstituted Compounds

Introduction

Matthias Helms is an esteemed inventor based in Linz, Austria. With a focus on innovative pharmaceutical processes, he has made significant contributions to the field of chemistry. His work has led to the advancement of techniques for synthesizing complex compounds, which are pivotal in various applications.

Latest Patents

Matthias Helms holds two patents that showcase his expertise in the synthesis of trisubstituted 3,4-dihydro-isoquinoline derivatives. His first patent details a process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative. This innovative process involves the hydrogenation of a specific compound using bis[chloro-1,5-cyclooctadiene-iridium] combined with a unique catalyst, (S)-i-dicyclohexylphosphino-2-[(S)-α-(dimethylamino)-2-(dicyclohexylphosphino)benzyl]-ferrocene.

The second patent also revolves around the trisubstituted 3,4-dihydro-1H-isoquinolin compound, detailing not only its preparation process but also its potential applications. This work exemplifies Helms' commitment to advancing synthetic methodologies in the pharmaceutical realm.

Career Highlights

Throughout his career, Matthias Helms has been associated with Actelion Pharmaceuticals Ltd., a company known for its innovative solutions in the pharmaceutical industry. His work at Actelion has enabled him to influence and contribute to cutting-edge research, particularly in drug development.

Collaborations

Matthias Helms collaborates closely with his colleagues, including Doris Domin and Christoph Imboden. These partnerships foster a collaborative environment that enhances creativity and innovation in their projects, further propelling their research and development efforts.

Conclusion

In conclusion, Matthias Helms stands out as a notable inventor with two significant patents that contribute to the field of pharmaceutical chemistry. His innovative processes and collaborations reflect his dedication to advancing scientific knowledge and improving drug formulations, making him a vital asset in the industry.